Status:

ACTIVE_NOT_RECRUITING

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Lead Sponsor:

Intra-IMMUSG Pte Ltd

Collaborating Sponsors:

Parexel

Conditions:

Solid Tumor

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.

Detailed Description

The study consists of a Screening Period (Day - 14 to Day -1), a Treatment Period during which visits will occur every 2 weeks, an End of Treatment visit within 14 days of the decision to discontinue ...

Eligibility Criteria

Inclusion

  • Patients with unresectable or metastatic solid tumors willing to provide signed informed consent.
  • Histopathological diagnosis and metastatic status cancer at study entry.
  • Must have received at least 1 prior line of systemic therapy for metastatic disease but no more than 3 prior lines of treatment for metastatic disease.
  • Life expectancy of more than 6 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score or less than 2.
  • Adequate organ and hematological function.
  • Measurable disease by RECIST v1.1 and iRECIST.

Exclusion

  • Patient has known untreated or symptomatic central nervous system metastasis.
  • Patient is receiving systemic glucocorticoids or other immunosuppressive treatments for autoimmune disease or any other medical condition.
  • Patient has experienced a severe hypersensitivity reaction to another monoclonal antibody.
  • Patient has received treatment with any systemic anti-cancer therapies within 3 weeks prior to starting study treatment.
  • Patient has undergone radiotherapy ≤ 4 weeks prior to starting study treatment.
  • Patient has received \> 3 lines of prior systemic chemotherapy for metastatic disease

Key Trial Info

Start Date :

December 12 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2026

Estimated Enrollment :

51 Patients enrolled

Trial Details

Trial ID

NCT04452955

Start Date

December 12 2020

End Date

March 1 2026

Last Update

December 2 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

HonorHealth Research

Scottsdale, Arizona, United States, 85258

2

St. Jude Medical Center

Fullerton, California, United States, 92835

3

The Angeles Clinic

Los Angeles, California, United States, 90025

4

Norton Healthcare

Louisville, Kentucky, United States, 40200